Quotes 5-day view Delayed Nyse
01/23/2023
01/24/2023
01/25/2023
01/26/2023
01/27/2023
Date
467.04(c)
457(c)
456.69(c)
475.91(c)
478.96
Last
126 149
142 022
107 277
199 792
132 984
Volume
+2.13%
-2.15%
-0.07%
+4.21%
+0.64%
Change
Estimated financial data (e) (USD)
Sales 2022
2 821 M
-
-
Net income 2022
-3 660 M
-
-
Net cash position 2022
4 268 M
-
-
P/E ratio 2022
-
Yield 2022
-
Sales 2023
2 903 M
-
-
Net income 2023
458 M
-
-
Net cash position 2023
4 758 M
-
-
P/E ratio 2023
-
Yield 2023
-
Capitalization
13 908 M
13 908 M
-
EV / Sales 2022
3,42x
EV / Sales 2023
3,15x
Nbr of Employees
7 900
Free-Float
70,5%
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows:
- manufacture of clinical diagnostic tests and automated test systems (51.9%). The group also offers test kits, quality control systems and related IT systems;
- manufacture of reagents,...
Ratings of Bio-Rad Laboratories, Inc.
All news about BIO-RAD LABORATORIES, INC.
01/10 Transcript : Bio-Rad Laboratories, Inc. Presents at 41st Annual J.P. Morgan H.. CI
01/10 Bio-rad Laboratories, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (.. AQ
01/06 Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, Febr.. BU
01/04 Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference BU
2022 RBC Initiates Bio-Rad Laboratories at Outperform, Sets Price Target at $565, Cites Reve.. MT
2022 Bio-Rad Expands Range of Quality Controls for Abbott Clinical Diagnostics Platforms AQ
2022 Transcript : Bio-Rad Laboratories, Inc. Presents at Credit Suisse 31st Annual.. CI
2022 Bio-rad Laboratories, Inc. : Regulation FD Disclosure (form 8-K) AQ
2022 Bio-Rad Laboratories, Inc. and NuProbe USA Enter Into an Exclusive Licensing Agreement .. CI
2022 Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare C.. AQ
2022 Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare C.. BU
2022 BIO-RAD LABORATORIES, INC. Management's Discussion and Analysis of Financial Condition.. AQ
2022 Bio-Rad Laboratories Posts Lower Q3 Net Income, Revenue; Shares Fall Friday MT
2022 Credit Suisse Adjusts Bio-Rad Laboratories' Price Target to $640 From $715, Keeps Outpe.. MT
2022 Bio-rad : Q3 Earnings Snapshot AQ
News in other languages on BIO-RAD LABORATORIES, INC.
Analyst Recommendations on BIO-RAD LABORATORIES, INC.
ETFs positioned on BIO-RAD LABORATORIES, INC. ETFs and Trackers with Trackinsight
Chart BIO-RAD LABORATORIES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIO-RAD LABORATORIES, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
4
Last Close Price
478,96 $
Average target price
588,75 $
Spread / Average Target
22,9%
Please enable JavaScript in your browser's settings to use dynamic charts.